Development of passive immunity against SARS-CoV-2 for management of immunodeficient patients-a perspective
- PMID: 32413374
- PMCID: PMC7215168
- DOI: 10.1016/j.jaci.2020.04.043
Development of passive immunity against SARS-CoV-2 for management of immunodeficient patients-a perspective
Keywords: COVID-19; IVIG; immunodeficiency; mAb; passive immunity; plasma therapy.
Comment on
-
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18. N Engl J Med. 2020. PMID: 32187464 Free PMC article. Clinical Trial.
-
Compassionate Use of Remdesivir for Patients with Severe Covid-19.N Engl J Med. 2020 Jun 11;382(24):2327-2336. doi: 10.1056/NEJMoa2007016. Epub 2020 Apr 10. N Engl J Med. 2020. PMID: 32275812 Free PMC article.
References
-
- Borba M.G.S., Val F.F.A., Sampaio V.S., Alexandre M.A.A., Melo G.C., Brito M. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. JAMA Netw Open. 2020;3 - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
